If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
The acquisition marks Anupam Rasayan’s strategic entry into the pharmaceutical formulations segment
Revenue from operations climbed 13% to Rs. 886.87 crore
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
Expands Davaindia network to 2,579 stores
If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings
The decision marks a key step in the centralized EU review process
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
With standout ADC and t-cell engager response data across hard-to-treat cancers
Subscribe To Our Newsletter & Stay Updated
